XPO (NYSE:XPO) Q4 2025 Earnings call February 05, 2026 08:30 AM ET Speaker11Welcome to the XPO fourth quarter 2025 earnings conference call and webcast. My name is Shamali, and I will be your operator for today's call. At this time, all participants are in a listen-only mode. Later, we will conduct a question-and-answer session. If you have a question, please dial *1 on your telephone keypad. Please limit yourself to one question when you come up in the queue. If you have additional questions, you're welcom ...

The Hershey Company (NYSE:HSY) Q4 2025 Earnings call February 05, 2026 08:30 AM ET Speaker2Greetings and welcome to The Hershey Company fourth quarter 2025 question and answer session. To join the question queue, please press star 1 on your telephone keypad. At this time, all participants are in a listen-only mode. As a reminder, this conference is being recorded. I'd now like to turn the call over to your host, Anoori Naughton, Vice President of Investor Relations for The Hershey Company. Thank you. You ma ...

Omnicell (NasdaqGS:OMCL) Q4 2025 Earnings call February 05, 2026 08:30 AM ET Speaker7Hello, and welcome to the Omnicell Fiscal Year and Fourth Quarter 2025 results. All lines have been placed on mute to prevent any background noise. After the speaker's remarks, there will be a question and answer session. If you would like to ask a question during this time, simply press Star, followed by the number 1 on your telephone keypad. If you would like to withdraw your question, press Star 1 again, and please note ...

Financial Data and Key Metrics Changes - The meeting discussed the election of directors, advisory vote on executive compensation, and the ratification of Ernst & Young as the independent accounting firm for the fiscal year ending August 31, 2026 [2][8] - The advisory vote on executive compensation received approval from no less than 98% of shares present and voting [11] - The ratification of Ernst & Young was approved by no less than 99% of shares present and voting [11] Business Line Data and Key Metrics Changes - No specific data on business line performance was provided during the meeting [2][4] Market Data and Key Metrics Changes - No specific market data or metrics were discussed during the meeting [2][4] Company Strategy and Development Direction - The company is focused on maintaining strong governance through the election of directors and ensuring transparency in executive compensation [2][8] - The selection of Ernst & Young as the independent auditor reflects the company's commitment to high standards of financial reporting [11] Management Comments on Operating Environment and Future Outlook - Management did not provide specific comments on the operating environment or future outlook during this meeting [2][4] Other Important Information - A quorum was confirmed with at least 95% of shares represented, allowing the meeting to proceed [6][10] - The company emphasized the importance of compliance with SEC regulations regarding the disclosure of material information [13][14] Q&A Session Summary - No questions were submitted during the Q&A session, and management reiterated the limitations on discussing material non-public information [13][14]

The Cigna Group (NYSE:CI) Q4 2025 Earnings call February 05, 2026 08:30 AM ET Speaker11Ladies and gentlemen, thank you for standing by for The Cigna Group's fourth quarter 2025 results review. At this time, all callers are in a listen-only mode. We will conduct a question-and-answer session later during the conference and review procedures on how to inquire to ask questions at that time. If you should require assistance during the call, please press star zero on your touch-tone phone. As a reminder, ladies ...

Stewart Information Services (NYSE:STC) Q4 2025 Earnings call February 05, 2026 08:30 AM ET Speaker3Hello and thank you for joining the Stewart Information Services Corporation's fourth quarter and full year 2025 earnings call. At this time, all participants are in a listen-only mode. Later, you will have the opportunity to ask a question during the question and answer session. Instructions will be given at that time. Please note today's call is being recorded. Lastly, if you should require operator assista ...

Prestige Consumer Healthcare (NYSE:PBH) Q3 2026 Earnings call February 05, 2026 08:30 AM ET Speaker1day and thank you for standing by. Welcome to the third quarter, 2026, Prestige Consumer Healthcare Inc. earnings conference call. At this time, all participants are in a listen-only mode. After the speaker's presentation, there will be a question-and-answer session. To ask a question during the session, you will need to press star 11 on your telephone. You will then hear an automated message advising your ha ...

MasterCraft Boat (NasdaqGM:MCFT) Q2 2026 Earnings call February 05, 2026 08:30 AM ET Speaker9Ladies and gentlemen, thank you for standing by, and welcome to the MasterCraft Boat Holdings Fiscal Second Quarter 2026 Earnings Conference Call. Please be advised that today's conference is being recorded. At this time, all participants are on a listen-only mode. After the speaker's presentation, there will be a question-and-answer session. To ask a question during the session, you'll need to press star one one on ...

Alico (NasdaqGS:ALCO) Q1 2026 Earnings call February 05, 2026 08:30 AM ET Speaker4Thank you for your continued patience. Your meeting will begin shortly. If you need assistance at any time, please press star zero and a member of our team will be happy to help you. Thank you for your continued patience. Your meeting will begin shortly. If you need assistance at any time, please press star zero and a member of our team will be happy to help you.Please stand by. Your meeting is about to begin. Good morning, an ...

Novo Nordisk (NYSE:NVO) Q4 2025 Earnings call February 05, 2026 08:15 AM ET Company ParticipantsJames Gordon - Director, Head of European Pharma and Biotech & Life Sciences Equity ResearchKarsten Munk Knudsen - CFOMartin Holst Lange - Chief Scientific OfficerMike Doustdar - CEOSachin Jain - European Healthcare Equity ResearchSimon Baker - Head of Global Biopharma ResearchConference Call ParticipantsEvan Seigerman - Managing Director, Head of Healthcare Research, Senior Biotechnology and Pharmaceutical Analy ...